Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Bioverativ

- PMLiVE

Sanofi/Sobi’s haemophilia A therapy shows ‘highly effective’ bleed protection in children

The rare bleeding disorder affects approximately one in every 5,000 male births annually

- PMLiVE

Sanofi/Regeneron’s Dupixent shows significant improvements in paediatric eosinophilic oesophagitis

The chronic inflammatory disease affects approximately one in 2,000 people in the US

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing MS study

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

- PMLiVE

Sanofi and Belharra Therapeutics enter $700m immunological disease collaboration

The partnership will utilise Belharra’s platform to identify and advance small molecules against immunology targets

- PMLiVE

Sanofi/Regeneron’s Kevzara approved by FDA for polyarticular juvenile idiopathic arthritis

The chronic disease is designated as one of the three major types of juvenile idiopathic arthritis

- PMLiVE

Sanofi shares positive late-stage results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Amgen’s Uplizna shows promise in rare fibroinflammatory disease IgG4-RD

The company is planning to file for US approval of the CD19-targeted drug in this patient population

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for uncontrolled COPD

No new treatment approaches have been approved for the respiratory disease in more than a decade

- PMLiVE

Sanofi’s multiple myeloma treatment Sarclisa accepted for FDA priority review

The second most common haematologic malignancy is responsible for more than 180,000 new global diagnoses every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links